Related Experiment Videos
Involvement of iron in MPP+ toxicity in substantia nigra: protection by desferrioxamine
E R Matarredona1, M Santiago, J Cano
1Departamento de Bioquimica, Bromatologia y Toxicologia, Facultad de Farmacia, Universidad de Sevilla, Spain.
Abstract:
Desferrioxamine (DES) protective effect against 1-methyl-4-phenylpyridinium (MPP+) toxicity was evaluated by microdialysis in the substantia nigra. DES (1 microM to 10 mM) co-perfused with MPP+ (2.5 mM) on day 1, produced on day 2 a higher dopamine extracellular output after perfusion of MPP+ than in control-MPP+ perfusion experiments, in which no DES was administered on day 1. Both Ringer's perfusion alone (control-Ringer) and co-perfusion of DES (10 mM) with MPP+ (2.5 mM) on day 1 produced on day 2 similar increases in dopamine extracellular output after a second MPP+ perfusion. In the control-Ringer experiment, note that the MPP+ on day 2 is the first MPP+ perfusion. Perfusion of FeCl3 (200 microM) along with MPP+ (2.5 mM) and DES (100 microM) on day 1 completely abolished on day 2 the neuroprotective effect found with MPP+ (2.5 mM) and DES (100 microM). The ability of DES to protect against MPP+ toxicity may indicate a therapeutic strategy in the treatment of diseases when iron is implicated.
Insights
Desferrioxamine (DES) protects against 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by increasing dopamine output. Iron chelation by DES may offer therapeutic potential for iron-related neurological diseases.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- 1-methyl-4-phenylpyridinium (MPP+) is a neurotoxin that selectively damages dopaminergic neurons in the substantia nigra.
- Iron is implicated in neurodegenerative processes, and its dysregulation can exacerbate neuronal damage.
- Desferrioxamine (DES) is an iron chelator with potential neuroprotective properties.
Purpose of the Study:
- To evaluate the protective effect of Desferrioxamine (DES) against 1-methyl-4-phenylpyridinium (MPP+) induced toxicity in the substantia nigra.
- To investigate the role of iron in mediating MPP+ neurotoxicity and the potential of DES as a therapeutic agent.
Main Methods:
- Microdialysis was used to measure extracellular dopamine levels in the substantia nigra.
- Animals were perfused with varying concentrations of DES and MPP+, with or without FeCl3, on day 1.
- Dopamine output was assessed on day 2 following a second MPP+ perfusion.
Main Results:
- Co-perfusion of DES with MPP+ on day 1 significantly increased dopamine extracellular output on day 2 compared to MPP+ alone.
- The neuroprotective effect of DES was abolished when iron (FeCl3) was co-administered, suggesting iron's role in MPP+ toxicity.
- DES demonstrated a dose-dependent protective effect against MPP+ induced neurotoxicity.
Conclusions:
- Desferrioxamine (DES) exhibits a protective effect against MPP+ induced neurotoxicity in the substantia nigra.
- Iron chelation by DES appears to be the mechanism underlying its neuroprotective action.
- These findings suggest that DES could be a potential therapeutic strategy for neurodegenerative diseases where iron dysregulation plays a role.